use
combin
therapi
includ
nonstudi
antibiot
investig
note
differ
antibiot
use
randomis
group
studi
antibiot
account
antibiot
use
cycl
mix
group
respect
primari
endpoint
investig
find
signific
differ
mean
preval
antibioticresist
gramneg
bacteria
patient
carriag
cycl
vs
mix
even
consid
incid
rate
ratio
deriv
mix
effect
analysi
adjust
potenti
confound
ci
differ
observ
sever
subgroup
analys
result
thu
strongli
suggest
cycl
antibiot
benefici
effect
antibiot
mix
emerg
antibiot
resist
gramneg
bacteria
trial
leav
us
studi
neg
outcom
find
consist
theoret
argument
howev
neg
studi
still
highli
inform
studi
qualiti
high
mean
suffici
statist
power
avoid
type
ii
error
high
protocol
adher
thorough
statist
analysi
account
potenti
bias
trial
report
van
duijn
colleagu
fulfil
criteria
studi
protocol
investig
predefin
statist
approach
use
differ
sensit
analys
suffici
power
detect
effect
present
high
adher
studi
protocol
observ
despit
two
major
deviat
one
data
exclud
due
miss
pointpreval
inform
anoth
washout
period
prolong
due
outbreak
carbapenemresist
klebsiella
pneumonia
therefor
obviou
reason
anoth
trial
would
contradict
find
howev
reduct
preval
antibioticresist
gramneg
bacteria
icu
remain
prioriti
urgent
need
find
new
institut
strategi
prove
benefici
clinic
trial
need
reinforc
patientlevel
tool
avail
includ
among
other
improv
hand
hygien
better
select
patient
need
antibiot
hostrespons
marker
procalcitonin
pathogen
marker
comment
diseas
passiv
transfer
convalesc
human
sera
investig
protect
coronavirus
sever
acut
respiratori
syndrom
arenavirus
lassa
junin
filovirus
ebola
marburg
pandem
influenza
virus
howev
posit
find
substanti
control
trial
immunoglobulin
licens
infecti
diseas
passiv
transfer
without
attend
risk
appendix
heterolog
equin
ovin
immun
globulin
induc
hypersensit
fab
f
ab
shorter
invivo
halfliv
lessen
hypersensit
suggest
hypersensit
larg
mediat
foreign
fc
although
human
igg
desir
risk
transmit
unidentifi
pathogen
costli
donor
screen
protocol
barrier
use
fraction
human
immun
plasma
product
exampl
clinic
studi
antim
intraven
immunoglobulin
report
difficulti
identifi
human
plasma
donor
low
neutralis
titr
convalesc
patient
gener
shortliv
natur
neutralis
antibodi
respons
coronaviru
infect
lancet
infecti
diseas
john
beigel
colleagu
report
result
firstinhuman
phase
clinic
trial
safeti
toler
fulli
human
polyclon
igg
develop
plasma
transchromosom
cattl
immunis
mer
spike
protein
nanoparticl
transchromosom
cattl
use
produc
develop
cours
decad
remark
feat
genet
engin
figur
research
studi
multipl
vaccin
platform
gener
antigenspecif
human
igg
transchromosom
cattl
hyperimmunis
transchromosom
cattl
anthrax
protect
antigen
yield
human
neutralis
antibodi
protect
mice
anthrax
challeng
addit
dna
vaccin
yield
human
neutralis
antibodi
demonstr
efficaci
passiv
transfer
rodent
model
ebola
viru
hantaviru
infect
immunis
recombin
nanoparticl
use
product
gammairradi
wholekil
virion
induc
antim
neutralis
human
igg
transchromosom
cattl
reportedli
reduc
lung
viral
load
nonleth
murin
mer
challeng
studi
beigel
colleagu
show
human
particip
receiv
infus
develop
antim
neutralis
antibodi
titr
correl
serum
concentr
titr
achiev
without
clinic
signific
hypersensit
advers
event
infus
rate
current
intraven
immunoglobulin
guidelin
termin
elimin
halflif
appear
within
rang
typic
human
antibodi
enrich
human
could
exhibit
import
invivo
effectormedi
function
addit
demonstr
invitro
neutralis
capabl
effect
bovin
process
human
igg
develop
unclear
compar
immunolog
human
be
cattl
point
sever
key
innat
immun
factorsnam
anatom
eg
primari
lymphoid
organ
bovin
intestin
refer
mlenni
optimis
sequenti
knockout
heavychain
loci
bovin
fibroblast
introduc
hac
contain
human
immunoglobulin
heavi
ileal
peyer
patch
cellular
eg
abund
bovin
circulatori
cell
uniqu
capabl
molecular
eg
bovin
pattern
recognit
receptor
function
factor
could
lead
distinct
adapt
immun
posttransl
modif
includ
glycosyl
could
lead
dissimilar
effector
function
transchromosom
igg
human
igg
requir
addit
work
understood
transchromosom
cattl
reportedli
make
g
human
igg
per
anim
per
month
thu
cow
would
need
produc
immedi
mgkg
dose
unfraction
human
igg
one
million
adult
potent
function
antigenspecif
antibodi
gener
optimis
vaccin
protocol
crucial
environment
econom
feasibl
platform
therapeut
protect
efficaci
human
infect
lethal
anim
challeng
report
underscor
earli
technolog
requir
clinic
investig
vital
field
antibodi
deploy
infecti
diseas
support
concomit
rise
system
rapid
deliveri
rigor
select
highli
potent
monoclon
antibodi
protein
dna
rna
well
vector
deliveri
addit
technolog
address
need
sustain
potent
antibodi
therapi
includ
engin
bispecif
antibodi
halflif
extens
modif
studi
transchromosom
cattl
abil
produc
polyclon
antibodi
respons
emerg
pathogen
advanc
platform
worthi
consider
possibl
outbreak
situat
well
protect
atrisk
popul
wistar
institut
philadelphia
pa
usa
dweiner
wistarorg
dbw
laboratori
receiv
grant
fund
industri
collabor
dbw
receiv
speak
honoraria
fee
consult
board
servic
includ
serv
scientif
committe
board
director
remuner
includ
direct
payment
stock
stock
option
dbw
also
report
potenti
conflict
interest
inovio
merck
pfizer
janssen
vgxi
medimmun
bill
melinda
gate
foundat
stce
declar
compet
interest
long
road
toward
safe
effect
treatment
chronic
chaga
diseas
chaga
diseas
chronic
system
parasitosi
kinetoplastid
protozoon
trypanosoma
cruzi
lead
caus
cardiac
morbid
mortal
poor
rural
suburban
area
latin
america
sourc
largest
parasit
diseas
burden
american
contin
burden
spread
worldwid
owe
intern
migrat
recent
chang
scientif
understand
pathogenesi
chronic
chaga
diseas
led
consensu
cruziseroposit
patient
receiv
aetiolog
treatment
antit
cruzi
drug
current
avail
drug
nitroheterocycl
compound
benznidazol
nifurtimox
develop
empir
year
ago
effect
acut
congenit
earli
chronic
paediatr
chaga
diseas
observ
studi
preval
establish
chronic
diseas
indic
efficaci
substanti
lower
variabl
furthermor
recipi
either
drug
commonli
experi
advers
effect
lead
treatment
discontinu
